Therapeutic Recombinant Proteins : Next Generation

Not only recombinant proteins are now considered as excellent therapeutic approaches, but several blockbusters on the market belong to this class of molecules. Of the ten best-selling drugs in 2012, six of them were monoclonal antibody drugs, each with annual sales value exceeding US billion. Nevertheless, the field in terms of innovation is still very open and suggests business opportunities that are currently in development for some of them, or even, entering the market for the others.

On the 11th of November, the speakers of the “Therapeutic Recombinant Proteins - Next Generation” event will cover the wide range of business and innovation opportunities.

More details

Find an actor

LS2 Annual Meeting 201812.02.2018

The biggest Life Sciences conference in Switzerland takes place at the University of Lausanne February 12-13, 2018

Comment la «Health Valley» séduit les start-ups

«Ici, il y a une vraie convergence entre les technologies informatiques et le domaine médical, créant un...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn